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Introduction
Nowadays, around 80-85% of children with acute lym-
phoblastic leukemia (ALL) can be definitively cured through
the use of risk-oriented chemotherapy protocols.1-4 However,
there are still subsets of children with ALL in whom the prob-
ability of event-free survival with chemotherapy remains
unsatisfactory, because of the high chance of disease recur-
rence. 
Over the last years, much research on childhood ALL has
focused on the validation of biological and clinical prognostic
variables able to identify patients at high risk of relapse.
These characteristics predicting disease recurrence have var-
ied over time. Currently, some biological risk factors convey-
ing a dismal prognosis in childhood ALL can be identified
already at diagnosis. They include early thymocyte precursor
phenotype, cytogenetic anomalies such as t(9;22), t(4;11),
intrachromosomal amplification of chromosome 21 and
molecular lesions recently identified as predicting biological
resistance to conventional treatment (e.g. Ikaros mutations or
JAK2 mutations).5-8 Other prognostic factors, such as lack of
achievement of complete remission at the end of induction
therapy, reflect sensitivity of leukemia cells to treatment.9
Additionally, in the last years, response to induction treat-
ment, measured by evaluation of minimal residual disease,
was shown to have an even stronger predictive value on the
risk of leukemia recurrence.10,12
Over the past decades, differences in definition of high-
risk criteria and in frontline chemotherapy protocols among
the childhood ALL cooperative groups have produced vary-
ing results, with reported cure rates ranging from 30% to
60%.1-4,12-15
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Children with high-risk acute lymphoblastic leukemia in first complete remission can benefit from allogeneic
hematopoietic stem cell transplantation. We analyzed the outcome of 211 children with high-risk acute lym-
phoblastic leukemia in first complete remission who were given an allogeneic transplant between 1990 and 2008;
the outcome of patients who, despite having an indication for transplantation and a suitable donor, did not receive
the allograft for different reasons in the same time period was not analyzed. Sixty-nine patients (33%) were trans-
planted between 1990 and 1999, 58 (27%) between 2000 and 2005, and 84 (40%) between 2005 and 2008. A
matched family donor was employed in 138 patients (65%) and an unrelated donor in 73 (35%). The 10-year prob-
abilities of overall and disease-free survival were 63.4% and 61%, respectively. The 10-year cumulative incidences
of transplantation-related mortality and relapse were 15% and 24%, respectively. After 1999, no differences in
either disease-free survival or transplant-related mortality were observed in patients transplanted from unrelated
or matched family donors. In multivariate analysis, grade IV acute graft-versus-host disease was an independent
factor associated with worse disease-free survival. By contrast, grade I acute graft-versus-host disease and age at
diagnosis between 1 and 9 years were favorable prognostic variables. Our study, not intended to evaluate whether
transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete
remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most
recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.
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The dynamic evolution of the results obtained with
chemotherapy protocols has led to relevant modifications
of the eligibility criteria for allogeneic hematopoietic stem
cell transplantation (HSCT), so that, for instance, patients
with B-cell precursor ALL and more than 100x109/L white
blood cells at diagnosis not responding to the steroid pre-
phase should not be offered transplantation.
Several retrospective studies suggested that allogeneic
HSCT from an HLA-identical sibling improves the progno-
sis of high-risk ALL patients in first complete remission
compared with further intensified chemotherapy
protocols.16-20 In 1995, a prospective, cooperative random-
ized study was carried out through the collaboration
between the International Berlin-Frankfurt-Münster (I-
BFM) Study Group and the Pediatric Working Party of the
European Blood and Marrow Transplantation (EBMT)
Group with the aim of comparing the results of allogeneic
HSCT from a compatible related donor with those of chil-
dren with high-risk ALL in first complete remission diag-
nosed between 1995 and 2000 and treated with chemother-
apy alone.21 In this study, 357 children were enrolled, 280 of
whom received chemotherapy while the other 77 were
given chemotherapy followed by related-donor HSCT, on
the basis of genetic chance (i.e., availability of an HLA-iden-
tical donor). The 5-year disease-free survival was 40.6% in
children allocated to chemotherapy and 56.7% in those
given HSCT (P=0.02). Balduzzi et al. concluded that chil-
dren with high-risk ALL in first complete remission benefit
more from related-donor HSCT than from chemotherapy
alone. The gap between the two strategies increases as the
risk profile of the patient worsens. Indeed, children who
were eligible for the study because of induction failure ben-
efited more than others from related-donor availability.21
Based on the same cohort of patients they had previous-
ly analyzed, Balduzzi et al. recently discussed the impact
of the time elapsed in first complete remission on progno-
sis, as well as the potential influence of waiting time to
transplantation. The relative advantage of HSCT from
compatible related donors in high-risk childhood ALL was
found whatever the time elapsed from first complete
remission to HSCT.22
The issue of whether patients with high-risk ALL in first
complete remission should undergo HSCT from donors
other than an HLA-identical sibling remains controversial.
The outcome of unrelated donor HSCT has improved
greatly in recent years, mostly because of high-resolution
HLA-typing and improved prevention/treatment of graft-
versus-host disease (GvHD).23,24
In order to further investigate the impact of allogeneic
HSCT in high-risk ALL patients, we carried out a retro-
spective, multicenter study to analyze the outcome of 211
consecutive ALL pediatric patients who underwent HSCT
from a related or unrelated donor for ALL in first complete
remission and whose data were reported to the Italian
Association of Pediatric Hematology and Oncology
(AIEOP)-HSCT Registry between 1990 and 2008. 
Design and Methods
Between November 1990 and June 2008, 211 patients aged
over 12 months, with high-risk ALL in first complete remission
treated with a frontline AIEOP protocol, underwent allogeneic
HSCT in 19 Italian pediatric transplant centers.25,26 Among these
211 patients, 69 (33%) were given the allograft between 1990 and
1999, 58 (27%) between 2000 and 2005, and 84 (40%) between
2005 and 2008.
The clinical characteristics of the patients are reported in Table
1. In all donor-recipient pairs, histocompatibility was determined
by serology for HLA-A and HLA-B antigens and by DNA typing
for the HLA-DRB1 locus. In all patients transplanted with a graft
from an unrelated donor, HLA-DRB1 typing was performed by a
high-resolution allelic technique. After 1998, all class I and class
II HLA alleles (i.e. HLA-A, HLA-B, HLA-C, DRB1, and DQβ1)
were typed by a high-resolution DNA technique.
Eligibility criteria for HSCT are detailed in Table 2. In general,
patients with an estimated probability of event-free survival
below 40% in the various time periods of the study were consid-
ered to be eligible to receive HSCT. The 35 patients enrolled in
protocols AIEOP-ALL88 and AIEOP-ALL91 who received HSCT
had been considered eligible for allografting mainly because of a
poor prednisone response and either hyperleukocytosis or a T-
cell phenotype.  
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Table 1. Characteristics of the 211 patients enrolled in the study and their
transplants.
N. of patients                                                                              211 (100%)
Gender: male/female                                                                     138/73
Age at diagnosis (years, median, range)                             7.9 (1.1-18)
White blood cells count at diagnosis (x109/L)                  77 (0.39-494)
Immunophenotype                                                                              
B lineage                                                                                   113 (53.5%)
T lineage                                                                                      80 (38%)
Missing/unknown                                                                      18 (8.5%)
Karyotype                                                             
t(9;22)                                                                                          43 (20%)
t(4;11)                                                                                            14 (7%)
Chemotherapy protocol                                   
AIEOP ALL 88                                                                                6 (3%)
AIEOP ALL 91                                                                              29 (14%)
AIEOP ALL 95                                                                              32 (15%)
AIEOP ALL 2000                                                                         118 (56%)
Missing/unknown                                                                       26 (12%)
Age at HSCT (years, median, range)                                   8.5 (1.5-19.1)
Donor                                                                    
Matched family donor                                                             138 (65%)
Unrelated donor                                                                        73 (35%)
Conditioning regimen                                       
Total body irradiation                                                              190 (90%)
Chemotherapy alone                                                                21 (10%)
Stem cell source                                                
Bone marrow                                                                             186 (88%)
Peripheral blood                                                                         14 (7%)
Cord blood                                                                                   11 (5%)
GvHD prophylaxis                                          MFD                          UD                            Total
CSA                                                                    97                               1                                98
CSA + MTX                                                      19                               5                                24
CSA + MTX + ATG                                           -                               54                               54
CSA + PDN                                                       4                                -                                  4
CSA + PDN + ATG                                           -                                6                                 6
CSA + ATG                                                        2                                4                                 6
T-cell depletion                                                -                                3                                 3
Unknown                                                          16                               -                                 16
Data are expressed as medians and ranges or as percentages, as appropriate.  HSCT: hematopoi-
etic stem cell transplantation; AIEOP: Associazione Italiana di Ematologia e Oncologia Pediatrica
(Italian Association of Pediatric Hematology and Oncology); ALL: acute lymphoblastic leukemia;
GvHD: graft-versus-host disease; MFD: matched family donor; UD: unrelated donor; CSA:
cyclosporin-A; MTX: methotrexate; PDN: prednisone; ATG: anti-thymocyte globulin. 
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All parents or guardians signed the appropriate informed con-
sent, approved by the local ethics committee or Institutional
Review Board.
Minimal residual disease analysis and risk group 
stratification
Minimal residual disease was investigated in patients enrolled
in the AIEOP/BFM ALL-2000 protocol at two consecutive fol-
low-up time-points, namely on day 33 (TP1) and day 78 (TP2)
after the beginning of induction therapy, as described
elsewhere.27-34 Technical details are reported in the Online
Supplementary Material. Patients enrolled in the AIEOP-BFM 2000
protocol were stratified into different risk groups considering
also the results of minimal residual disease evaluation.26,35 For
reliable standard risk ratification, minimal residual disease nega-
tivity at TP1 and TP2 was required. Patients with high amounts
of residual disease (≥10-3) at TP2 were stratified in the minimal
residual disease-high-risk group. Minimal residual disease-inter-
mediate risk stratification was feasible in the case that minimal
residual disease was detected at either one or both time-points,
but at a level <10-3 at TP2. 
Statistical analysis
The criteria used for defining complete remission, neutrophil
and platelet engraftment, acute and chronic GvHD, transplant-
related mortality, relapse, overall survival, and disease-free sur-
vival are reported in the Online Supplementary Material.36,37
Overall and disease-free survival were calculated according to
the Kaplan-Meier method. Acute and chronic GvHD occurrence,
transplant-related mortality and relapse incidence were
expressed as cumulative incidence curves, in order to adjust the
analysis for competing risks. The significance of differences
between the disease-free survival curves was estimated by the
log–rank test (Mantel–Cox), while, in univariate analyses, Gray’s
test was used to assess differences between relapse incidence
and transplant-related mortality.38 A multivariate analysis on dis-
ease-free survival was performed using the Cox proportional
regression model,39 while the proportional sub-distribution haz-
ard regression model was used to perform multivariate analyses
of relapse incidence and transplant-related mortality. P values
<0.05 were considered to be statistically significant. Further
details on statistical analyses are presented in the Online
Supplementary Material.
Results
The median follow-up was 6.8 years (range, 1.6-18.9) for
surviving patients, and 0.9 years for patients who died
(range, 0.2-4.3). 
Engraftment and graft-versus-host disease 
Neutrophil and platelet engraftment occurred at a medi-
an of 16 (range, 8-44) and 24 (range, 11-97) days after
HSCT, respectively. Neutrophil engraftment was obtained
after 14.5 (range, 8-38) days for recipients of grafts from
matched family donors and 19 (range, 11-44) days for recip-
ients of unrelated donor grafts (P<0.0001). Platelet engraft-
ment for matched family donor and unrelated donor trans-
plant recipients was reached after a median time of 25.5
(range 11-81) and 25 (range, 12-97) days, respectively
(P=NS). Engraftment of children given cord blood cells was
delayed (data not shown).
Fifty-two patients did not develop acute GvHD (25%),
67 patients had grade I GvHD (32%), 62 patients grade II
(29%), 19 patients grade III (9%) and 11 patients developed
grade IV acute GvHD (5%). 
The cumulative incidence of grade III-IV acute GvHD
was 12% [95% confidence intervals (95% CI), 8-17]. It was
10% (95% CI, 6-17) and 15% (95% CI, 9-26) for matched
family donor and unrelated donor transplant recipients,
respectively (P=NS) and 12% (95% CI, 8-18) and 27%
(95% CI, 10-72) for bone marrow and peripheral blood
HSCT recipients, respectively (P=NS). No case of grade III-
IV acute GvHD was recorded in patients receiving cord
blood cells.  
HSCT in children with ALL in first CR
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Table 2. Eligibility criteria for transplantation with a graft from a matched family donor or unrelated donor in high-risk ALL.
AIEOP protocol HSCT eligibility criteria
MFD HSCT UD HSCT
AIEOP ALL 88 Eligibility criteria not specified Eligibility criteria not specified
AIEOP ALL 91 Eligibility criteria not specified Eligibility criteria not specified
AIEOP ALL 95 a. NRd33 a. NRd33
b. PPR + T lineage b. PPR + t(9;22)
c. PPR + pre-pre B lineage c. PPR + t(4;11)
d. PPR + WBC > 100x109/L at diagnosis
e. t(9;22)
f. t(4;11)
AIEOP-BFM ALL 2000 a. NRd33 a. NRd33
b. PPR + T lineage b. PPR + t(9;22)
c. PPR + pre-pre B lineage c. PPR + t(4;11)
d. PPR + WBC > 100x109/L at diagnosis d. MRD day +78≥10-2/L
e. t(9;22)
f. t(4;11)
g. MRD day +33≥10-2/L
e. MRD day +78≥10-3/L
MFD: matched  family donor; UD: matched unrelated donor; ALL: acute lymphoblastic leukemia; AIEOP: Associazione Italiana di Ematologia e Oncologia Pediatrica (Italian
Association of Pediatric Hematology and Oncology); HSCT: hematopoietic stem cell transplantation; NRd33: non-remission to induction treatment at day + 33; PPR: poor prednisone
response; WBC: white blood cell count, MRD: minimal residual disease.
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Considering recipient age, a higher incidence of grade III-
IV acute GvHD was observed in patients older than 15
years (35%; 95% CI, 19-67) than in patients aged between
1-9 years (10%; 95% CI, 6-17) or 10-14 years (9%; 95% CI,
4-19) (P=0.0084). 
One hundred forty-three patients did not develop chron-
ic GvHD (68%), 25 patients developed limited chronic
GvHD (12%), and 27 patients had extensive chronic GvHD
(13%). No data were available for the remaining 16 patients
(7%). The overall cumulative incidence of chronic GvHD
was 27% (95% CI, 21-34).
Overall and disease-free survival
The 10-year overall survival probability was 63.4% (95%
CI, 57-70) (Figure 1). The 10-year probability of disease-free
survival for all patients analyzed in the study was 61%
(95% CI, 54-68) (Figure 1). In univariate analyses, factors
influencing disease-free survival probability were the
patient’s age at diagnosis, and acute GvHD severity (Online
Supplementary Table S1, Figure 2A). 
Children aged between 1 and 9 years at diagnosis had a
better disease-free survival than those aged between 10-14
years, or older than 15 years: 68% (95% CI, 60-76), 55%
(95% CI, 43-67), and 34% (95% CI, 11-57), respectively,
P=0.026). The type of donor had an impact on disease-free
survival only among patients transplanted between 1990
and 1999: matched family donor, 65% (95% CI, 53-77);
unrelated donor, 33% (95% CI, 3-64), P=0.06). There were
no differences between recipients of matched family donor
or unrelated donor grafts for patients who underwent
HSCT after 2000 (Online Supplementary Table S1 and Figure
3A-C). 
In univariate analyses, the disease-free survival rate was
higher in patients with grade 0-II acute GvHD than in those
with grade III-IV acute GvHD: 65% (95% CI, 58-62) versus
40% (95% CI, 22-58), respectively; (P=0.002). Other vari-
ables had no impact on disease-free survival (see Online
Supplementary Table S1 for details). 
In multivariate analyses, the occurrence of grade IV acute
GvHD [RR=3.8 (95% CI, 1.58-9.20), P=0.002] was an inde-
F. Fagioli et al.
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Figure 1. Overall survival (SUR), disease-free survival (DFS), trans-
plant-related mortality (TRM) and relapse incidence (RI) of the whole
population analyzed. TRM and RI are expressed as cumulative inci-
dence curves, in order to adjust the analysis for competing risks.
Figure 2. (A) Disease-free survival, (B) relapse incidence and (C)
transplantation-related mortality according to severity of acute
GvHD.
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pendent factor associated with a worse disease-free sur-
vival rate. In contrast, the occurrence of grade I acute
GvHD was an independent favorable prognostic variable
for disease-free survival [RR=0.54 (95% CI, 0.29-0.99),
P=0.05) as was age at diagnosis between 1 and 9 years
(P=0.045) (Table 3).
Relapse incidence
The median time from HSCT to relapse was 8 months
(range, 2-28). The overall relapse incidence was 24%
(95% CI, 19-30) (Figure 1). In univariate analyses, patients
who underwent HSCT between 6 and 12 months or
within 6 months after diagnosis had a higher risk of
relapse than those transplanted more than 12 months
after diagnosis:  32% (95% CI, 23-46), 22% (95% CI, 16-
31), and 0%, respectively; (P=0.02).  
Moreover, patients with grade 0-I acute GvHD [30%
(95% CI, 23-40)] had a higher relapse incidence than
patients who developed grade II-IV acute GvHD [15%
(95% CI, 9-25); P=0.013]. 
None of the other variables analyzed was associated
with an increased incidence of relapse (Online
Supplementary Table S2, Figure 2B). In multivariate analy-
sis, both the time-interval between diagnosis and HSCT
and the occurrence of grade II-IV acute GvHD remained
independent prognostic variables for relapse incidence
(Table 3).
Transplant-related mortality
The overall cumulative incidence of transplant-related
mortality was 15% (95% CI, 11-21) (Figure 1). In univari-
ate analyses, factors significantly associated with an
increased risk of transplant-related mortality were age at
diagnosis and transplantation, year of transplantation by
donor type, stem cell source and occurrence of acute or
chronic GvHD (Online Supplementary Table S3).
In detail, transplant-related mortality was lower for
children aged 1-9 years at diagnosis as compared to those
aged 10-14 years or older than 15 years [8% (95% CI, 4-
15), 18% (95% CI, 11-31), and 54% (95% CI, 34-84),
respectively, P<0.00001]. Among the patients older than
15 years, we observed a marked reduction of transplant-
related mortality on the basis of the period of transplant
(1990-1999: 100%, 2000-2004: 65%, and 2005-2008:
16%, P=0.03) (Online Supplementary Table S3). 
It is noteworthy that the impact of the type of donor on
transplant-related mortality was only observed for
patients transplanted between 1990 and 1999 [unrelated
donor: 44% (95% CI, 21-92), matched family donor: 8%
(95% CI, 4-19), P=0.0043)]. There were no differences in
transplant-related mortality between patients transplant-
ed with grafts from matched family donors or unrelated
donors after 2000. A higher transplant-related mortality
was observed in patients receiving peripheral blood stem
cells than in patients transplanted with either cord blood
or bone marrow stem cells [45% (95% CI, 24-87), 21%
(95% CI, 8-58) and 13% (95% CI, 9-19), P=0.0062]. 
The transplant-related mortality rates of patients with
grade III and IV acute GvHD were 32% (95% CI, 16-61)
and 82% (95% CI, 62-100), respectively, versus 13% (95%
CI, 7-25), 3% (95% CI, 1-14) and 12% (95% CI, 6-26) for
patients with grade II, I and 0 acute GvHD, respectively
(P<0.00001) (Figure 2C). 
None of the other variables analyzed was associated
with an increased incidence of transplant-related mortali-
ty (Online Supplementary Table S3). When the Cox propor-
tional hazard regression model was applied, the strongest
predictors of transplant-related mortality were grade IV
acute GvHD [RR 18.1 (95% CI, 4.37-75.3), P<0.00001]
and unrelated donor for HSCT performed between 1990
HSCT in children with ALL in first CR
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Figure 3. Disease-free survival according to year of transplantation
and donor type: matched unrelated donor (MUD) or matched family
donor (MFD). (A) 1990-1999. (B) 2000-2004. (C) 2005-2008.
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and 1999 [RR 4.83 (95% CI, 1.43-16.3), P=0.01] (Table 3).
The causes of transplant-related mortality according to
year of transplant and donor type are reported in Online
Supplementary Table S4.
Minimal residual disease
Overall, among the patients who had been enrolled in
the AIEOP-BFM ALL-2000 protocol, 100 had minimal
residual disease results available at TP1 and TP2. On the
basis of these results, 27 out of these 100 patients were
classified as being at intermediate risk and 73 at high-risk. 
The influence of minimal residual disease on disease-free
survival, transplant-related mortality and relapse incidence
was then analyzed. The disease-free survival was 74%
(95% CI, 58-91) for intermediate-risk patients and 60%
(95% CI, 48-72) for high-risk children (P=0.369) (Online
Supplementary Table S1). Likewise, minimal residual disease
had no apparent effect on relapse incidence [intermediate-
risk: 19% (95% CI, 9-42), high-risk: 23% (95% CI, 15-35),
P=0.77] or transplant-related mortality [intermediate risk:
8% (95% CI, 2-29), high-risk: 17% (95% CI 10-30),
P=0.53] (Online Supplementary Tables S2 and S3).
Discussion
The prognosis of patients with childhood ALL has
improved dramatically over the past quarter of a century.
However, despite advances in the diagnosis and treatment
of childhood ALL, there are still subgroups of patients
who, after obtaining a first complete remission, have a
high risk of failing to benefit from current multiagent
chemotherapy regimens and, thus, require alternative
treatment strategies, such as allogeneic HSCT, to prevent
disease relapse.40,41
We analyzed a large series of pediatric and adolescent
patients with ALL, whose disease was defined as high-risk
according to the criteria of the different AIEOP protocols
running at the time of the allograft, and who underwent
either related or unrelated HSCT while in first complete
remission, from 1990 to 2008. This is a retrospective, mul-
ticenter study analyzing the outcome of 211 consecutive
ALL pediatric patients who received the allograft, while
we did not address the issue of patients who, despite hav-
ing an indication for HSCT and a suitable donor, did not
receive the allograft because of an event occurring before
the procedure or precluding its performance. Furthermore,
it should be emphasized that this study was not intended
to compare the results of HSCT with those obtained with
conventional chemotherapy. 
We found a 10-year disease-free survival rate of 61% in
the whole cohort of 211 patients. This result compares
favorably with those in other published studies on chil-
dren with high-risk ALL in first complete remission treat-
ed with allogeneic HSCT. Balduzzi et al. performed an
international prospective study showing that high-risk
ALL children in first complete remission who underwent
matched family donor HSCT had a 16% benefit in 5-year
disease-free survival compared with those who received
chemotherapy alone (56.7% versus 40.6%, P=0.02).
Similarly, the Children’s Oncology Group reported a 5-
year disease-free survival of 58.6% in a small cohort of
high-risk ALL patients in first complete remission who
received HSCT from a family member.41 It is noteworthy
that the probability of disease-free survival of our children
with t(9;22) approached 60%, a figure comparable to that
of Philadelphia chromosome-negative ALL patients and
should be considered remarkable having been mainly
obtained in patients treated in an era before the introduc-
tion of tyrosine kinase inhibitors.
Our results indicate that after 1999 transplant outcomes
are similar in recipients of grafts from unrelated donor or
matched family donors. Specifically, there were no obvi-
ous differences in disease-free survival, and most impor-
tantly, in the risk of transplant-related mortality. These
results are in agreement with previously published find-
ings by the Italian pediatric group in children or adoles-
cents with ALL in second complete remssion24,42 and sug-
F. Fagioli et al.
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Table 3. Multivariate analyses of variables influencing the probability of dis-
ease-free survival, and the cumulative incidence of transplant-related mortality,
and relapse.
RR (95% CI) P
Disease-free survival
Acute GvHD
Grade I vs. 0 0.54 0.29-0.99 0.05
Grade II vs. 0 0.56 0.30-0.98 0.07
Grade III vs. 0 1.04 0.46-2.32 0.92
Grade IV vs. 0 3.8 1.58-9.20 0.002
Age at diagnosis
10-14 y vs. 1-9 y 1.66 1.01-2.74 0.045
>15 y vs. 1-9 y 1.67 0.77-3.59 0.18
Donor type
UD vs.MFD 1.27 0.77-2.09 0.33
Year of transplant
2000-2004 vs. 1990-1999 0.63 0.34-1.18 0.15
2005-2008 vs. 1990-1999 0.55 0.29-1.03 0.06
Relapse incidence
Acute GvHD
Grade I vs. 0 0.80 0.42-1.54 0.52
Grade II vs. 0 0.47 0.22-1.01 0.05
Grade III vs. 0 0.39 0.11-1.40 0.15
Grade IV vs. 0 0 0 <0.00001
Interval between diagnosis 
and transplant
6-12 months vs. < 6 months 0.67 0.38-1.18 0.17
>12 months vs. < 6 months 0 0 <0.00001
Transplant-related mortality
Year of transplant by donor type 1.51 0.44-5.11 0.50
MFD 2000-2004 vs.MFD 1990-1999 0.56 0.13-2.40 0.44
MFD 2005-2008 vs.MFD 1990-1999
UD 1990-1999 vs.MFD 1990-1999 4.83 1.43-16.3 0.01
UD 2000-2004 vs. MFD 1990-1999 1.09 0.30-3.97 0.89
UD 2005-2008 vs. MFD 1990-1999 0.72 0.19-2.72 0.63
Age at diagnosis
10-14 y vs. 1-9 y 2.17 0.89-5.27 0.08
>15 y vs. 1-9 y 2.32 0.79-6.83 0.12
Acute GvHD
Grade I vs. 0 0.26 0.05-1.37 0.11
Grade II vs. 0 1.06 0.33-3.37 0.91
Grade III vs. 0 2.42 0.81-7.21 0.11
Grade IV vs. 0 18.1 4.37-75.3 <0.00001
Stem cell source
Cord blood vs. bone marrow 1.00 0.30-3.27 0.99
Peripheral bloos vs. bone marrow 2.35 0.54-10.1 0.25
GvHD:  graft-versus-host disease;  y: years; UD: unrelated donor;  MFD: matched family donor.
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gest that indications for HSCT in first complete remission
should be similar for patients with an HLA-identical sib-
ling or a matched unrelated donor.
We observed that the group of patients 10-14 years old
had a worse 10-year disease-free survival rate compared to
those 1-9 years old [RR 1.66 (95% CI 1.01-2.74), P=0.045].
The lower disease-free survival rate in the 10-14-year olds
was mainly due to a slightly higher transplant-related mor-
tality [RR 2.17 (95% CI 0.89-5.27), P=0.08], while the
relapse incidence was comparable. The transplant-related
mortality of adolescents (i.e. patients above 15 years of
age) was high, although a marked improvement was
observed over time. Thus, HSCT in ALL in first remission
in patients over 15 years old must be carefully weighed,
considering the pros and cons of alternative treatments.
The effect of the conditioning regimen on various trans-
plantation outcomes in children and adults with ALL was
recently analyzed by the International Bone Marrow
Transplant Registry.43,44 Among the patients with high-risk
ALL in first complete remission, a comparison of various
conditioning regimens, all including total body irradiation
combined with different cytotoxic drugs, did not show
any significant differences in transplant-related mortality,
relapse incidence and disease-free survival. In our cohort
of patients, we did not observe any differences in disease-
free survival, relapse incidence or early transplant-related
mortality between patients given either total body irradi-
ation or chemotherapy-based regimens (90% versus 10%
of patients), although the latter group included a limited
number of children. This observation needs to be con-
firmed by larger prospective randomized studies. 
We also analyzed the impact of risk stratification based
on minimal residual disease at day +33 and +78 after diag-
nosis on HSCT outcome. Minimal residual disease has
already proven to be the most sensitive method for eval-
uating treatment response and, thus, an important prog-
nostic factor for a better stratification of patients in differ-
ent risk classes in front-line treatment protocols.45,46
Recently, the AIEOP-BFM ALL 2000 multicenter trial
demonstrated the predictive role of minimal residual dis-
ease on relapse occurrence, the 5-year disease-free sur-
vival being 92.3%, 77.6%, and 50.1% for B-cell precursor
ALL and 91.1%, 80.6%, and 49.8% for T-cell precursor
ALL in patients defined as being at standard, intermediate
or high risk according to the minimal residual disease
findings.26,35 On these bases, the determination of minimal
residual disease also allows a better selection of those
patients who need the immunological effect of an allo-
graft to be cured. In accordance with the AIEOP-BFM cri-
teria, after 2000, the presence of minimal residual disease
≥10-2 at TP1 or ≥10-3 at TP2, as well as minimal residual
disease ≥10-2 at TP2, were considered independent indica-
tions for matched family donor or unrelated donor HSCT,
respectively. In this study, 27 and 73 out of the 100
patients investigated had minimal residual disease-inter-
mediate or high risk features, respectively. The 27 with
intermediate risk on the basis of minimal residual disease
were given the allograft because of the presence of other
characteristics rendering them classifiable as high-risk.
The probability of disease-free survival and relapse inci-
dence of patients at intermediate or high risk on the bases
of minimal residual disease were comparable. Thus,
although the number of patients investigated was limited,
our results seem to suggest that HSCT could reduce the
effects of minimal residual disease, evaluated during the
first 11 weeks of treatment, on patients’ outcome.
Unfortunately, we do not have data on pre-transplant
minimal residual disease, a variable shown to influence
patients’ outcome profoundly.10,47,48 It is reasonable to
hypothesize that, nowadays, pre-transplant minimal
residual disease is one of the most important prognostic
factors and that it is more important than intermediate
risk and high-risk minimal residual disease determinations
performed several months prior to HSCT.
Low-intensity GvHD prophylaxis has been reported to
facilitate better immune control of leukemia cells, this
resulting in a decreased risk of relapse.49 The benefit
offered by the occurrence of GvHD in terms of reduction
of disease recurrence can, however, be offset by a higher
incidence of transplant-related mortality. In our cohort,
considering patients who did not have acute GvHD as the
reference group, a lower relapse incidence was observed
in patients who developed grade II or grade IV acute
GvHD, although the latter had a transplant-related mor-
tality of 82%. In multivariate analysis, a significantly bet-
ter probability of disease-free survival was found only in
patients who developed grade I acute GvHD, while grade
II acute GvHD was associated with a trend towards better
disease-free survival. Collectively, these data suggest that
only mild GvHD can have a favorable impact on the final
outcome. 
We found an inverse correlation between the time
elapsed from diagnosis to HSCT and the risk of relapse.
Specifically, no relapses were reported in patients who
underwent HSCT more than 12 months after diagnosis,
while the relapse incidence was higher in those trans-
planted within 6 or 12 months from diagnosis. The most
plausible explanation for this finding might be that
patients who received HSCT more than 12 months after
diagnosis could have already been cured by chemothera-
py. However, we cannot rule out that longer chemothera-
py consolidation might have had a positive impact on
post-HSCT relapse risk. 
The higher transplant-related mortality observed in our
patients given peripheral blood progenitors confirms pre-
viously published data from Eapen et al.50 Thus, bone mar-
row must be preferentially chosen over peripheral blood
as the source of stem cells for children with either malig-
nant or non-malignant disorders, although, for the unre-
lated donor, the ultimate choice of the stem cell source
pertains to the donor. In the case the unrelated donor
chooses to donate peripheral blood stem cells, the risk of
performing transplantation must be evaluated carefully. 
In this study we demonstrated that remarkable progress
in terms of reduction of transplant-related mortality has
been achieved over the years, especially for transplants
performed after 2000. Specifically, we observed no deaths
from bleeding complications in patients transplanted after
2000, which is reasonably attributable to the improve-
ment of supportive care (Online Supplementary Table S4).
In conclusion, our data indicate that allogeneic HSCT is
a suitable option for a subgroup of children with ALL in
first complete remission with well-defined high-risk fea-
tures. Since the outcome of recipients of grafts from
matched family donors or unrelated donors was compara-
ble in the most recent period, the indications for transplan-
tation from either an HLA-identical sibling or an unrelated
volunteer should now be considered identical. Overall,
these indications changed significantly over time and are
now more restricted than those adopted in past years.
HSCT in children with ALL in first CR
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